Regeneron presents expanded Sanofi alliance worth up to $8 billion in potential payments
Bitget2026/10/30 12:26- Regeneron's expanded Sanofi alliance includes $1 billion upfront, up to $7 billion in milestones and a 50:50 global profit split.
- Third-quarter 2026 revenue totaled $5.1 billion; non-GAAP diluted earnings reached $20.07 per share.
- Dupixent global net sales rose 35% to $6.5 billion, with more than 1.5 million patients on therapy globally.
- Sanofi collaboration revenue increased 68% to $2.7 billion, reflecting a full share of profits for the first time.
- A Phase 3 trial of fianlimab with cemiplimab missed its primary endpoint against pembrolizumab in first-line metastatic melanoma.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Pre-orders for GTA 6 are booming and may reverse the downward trend! Citigroup raises Take-Two Interactive Software (TTWO.US) target to $270
Citigroup maintains a "Buy" rating on Take-Two Interactive Software, with a target price of $270.
Silver Price Forecast: XAG/USD trades flat around $53 ahead of US inflation data
Swiss Franc holds ground as US Dollar consolidates ahead of CPI inflation data
Net profit surges fivefold but masks decline in core business; crypto mining companies' shift to AI poses hidden risks
Marathon Holdings' Q3 net profit reached $632 million, up 413% year-on-year. However, its mining revenue declined by 35%. The company relied on selling 13,500 BTC to pay off debts and is now betting on AI infrastructure, increasing the risk of an imbalanced profit structure.
Crypto prices
More
